Piper Jaffray Initiates Auspex Pharma At Overweight

Analysts at Piper Jaffray initiated coverage on shares of Auspex Pharma

with a Overweight rating. The target price for Auspex Pharma is set to $50. Auspex Pharma shares surged 0.48% to close at $27.16 yesterday.